Skip to main content
Erschienen in: Endocrine 3/2018

06.02.2018 | Review

Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review

verfasst von: Panagiotis Anagnostis, Stavroula A. Paschou, Nifon N. Gkekas, Aikaterini-Maria Artzouchaltzi, Konstantinos Christou, Dimitrios Stogiannou, Andromachi Vryonidou, Michael Potoupnis, Dimitrios G. Goulis

Erschienen in: Endocrine | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Both type 1 (T1DM) and type 2 diabetes mellitus (T2DM) have been associated with bone fragility and increased fracture risk. However, little is known regarding the effect of anti-osteoporotic treatment on bone mineral density (BMD) and/or fracture risk in these patients. We aimed to systematically investigate the efficacy of anti-osteoporotic medications in patients with diabetes in comparison with non-diabetic subjects.

Methods

MEDLINE and Scopus databases were searched (up to 31st October 2017).

Results

Nine studies fulfilled the pre-defined inclusion criteria [patients with T2DM (n = 8) or either T1DM or T2DM (n = 1)]. Regarding fracture risk, five studies were identified. Alendronate demonstrated comparable vertebral anti-fracture efficacy in patients with and without diabetes (n = 2), whereas non-vertebral fracture risk was either the same (n = 1) or higher in diabetic patients (n = 1). Raloxifene also demonstrated comparable vertebral anti-fracture efficacy in both groups (n = 2), without any effect on non-vertebral fractures in either group. In one study, diabetic patients exposed to raloxifene demonstrated the same vertebral and non-vertebral fracture risk with non-diabetic patients. Teriparatide (n = 1) demonstrated the same non-vertebral fracture rates in both patients with and without T2DM. Regarding BMD, equal increases in spine BMD were observed with alendronate (n = 4), risedronate (n = 1), and teriparatide (n = 1). With respect to hip BMD, similar increases were observed with teriparatide (n = 1), whereas data regarding alendronate were controversial (n = 3). No eligible study was found for zoledronic acid, ibandronate, strontium ranelate, denosumab, or bazedoxifene.

Conclusions

The presence of diabetes does not alter anti-osteoporotic treatment response, regarding BMD increase and vertebral fracture risk reduction.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat S. Epstein, D. Leroith, Diabetes and fragility fractures–a burgeoning epidemic? Bone 43, 3–6 (2008)CrossRefPubMed S. Epstein, D. Leroith, Diabetes and fragility fractures–a burgeoning epidemic? Bone 43, 3–6 (2008)CrossRefPubMed
4.
Zurück zum Zitat J.C. Krakauer, M.J. McKenna, N.F. Buderer, D.S. Rao, F.W. Whitehouse, A.M. Parfitt, Bone loss and bone turnover in diabetes. Diabetes 44, 775–782 (1995)CrossRefPubMed J.C. Krakauer, M.J. McKenna, N.F. Buderer, D.S. Rao, F.W. Whitehouse, A.M. Parfitt, Bone loss and bone turnover in diabetes. Diabetes 44, 775–782 (1995)CrossRefPubMed
5.
Zurück zum Zitat M. Janghorbani, R.M. Van Dam, W.C. Willett, F.B. Hu, Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am. J. Epidemiol. 166, 495–505 (2007)CrossRefPubMed M. Janghorbani, R.M. Van Dam, W.C. Willett, F.B. Hu, Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am. J. Epidemiol. 166, 495–505 (2007)CrossRefPubMed
6.
Zurück zum Zitat P. Vestergaard, Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos. Int. 18, 427–444 (2007)CrossRefPubMed P. Vestergaard, Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos. Int. 18, 427–444 (2007)CrossRefPubMed
7.
Zurück zum Zitat J.A. Kanis, O. Johnell, A. Oden, H. Johansson, E. McCloskey, FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 19, 385–397 (2008)CrossRefPubMedPubMedCentral J.A. Kanis, O. Johnell, A. Oden, H. Johansson, E. McCloskey, FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 19, 385–397 (2008)CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat C. Adil, T. Aydın, Ö. Taşpınar, et al., Bone mineral density evaluation of patients with type 2 diabetes mellitus. J. Phys. Ther. Sci. 27, 179–182 (2015).CrossRefPubMedPubMedCentral C. Adil, T. Aydın, Ö. Taşpınar, et al., Bone mineral density evaluation of patients with type 2 diabetes mellitus. J. Phys. Ther. Sci. 27, 179–182 (2015).CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat E.K. Caglayan, Y. Engin-Ustun, N. Sari, S. Karacavus, L. Seckin, M. Kara, Evaluation of bone density measurement in type 2 diabetic postmenopausal women with hypertension and hyperlipidemia. J. Menopausa. Med. 21, 36–40 (2015)CrossRef E.K. Caglayan, Y. Engin-Ustun, N. Sari, S. Karacavus, L. Seckin, M. Kara, Evaluation of bone density measurement in type 2 diabetic postmenopausal women with hypertension and hyperlipidemia. J. Menopausa. Med. 21, 36–40 (2015)CrossRef
10.
Zurück zum Zitat J.N. Farr, M.T. Drake, S. Amin, L.J. Melton 3rd, L.K. McCready, S. Khosla, In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J. Bone Miner. Res. 29, 787–795 (2014)CrossRefPubMedPubMedCentral J.N. Farr, M.T. Drake, S. Amin, L.J. Melton 3rd, L.K. McCready, S. Khosla, In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J. Bone Miner. Res. 29, 787–795 (2014)CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat V. Mpalaris, P. Anagnostis, D.G. Goulis, I. Iakovou, Complex association between body weight and fracture risk in postmenopausal women. Obes. Rev. 16, 225–233 (2015)CrossRefPubMed V. Mpalaris, P. Anagnostis, D.G. Goulis, I. Iakovou, Complex association between body weight and fracture risk in postmenopausal women. Obes. Rev. 16, 225–233 (2015)CrossRefPubMed
12.
Zurück zum Zitat N. Napoli, M. Chandran, D.D. Pierroz, B. Abrahamsen, A.V. Schwartz, S.L. Ferrari; IOF Bone and Diabetes Working Group, Mechanisms of diabetes mellitus-induced bone fragility. Nat. Rev. Endocrinol. 13, 208–219 (2017)CrossRefPubMed N. Napoli, M. Chandran, D.D. Pierroz, B. Abrahamsen, A.V. Schwartz, S.L. Ferrari; IOF Bone and Diabetes Working Group, Mechanisms of diabetes mellitus-induced bone fragility. Nat. Rev. Endocrinol. 13, 208–219 (2017)CrossRefPubMed
13.
Zurück zum Zitat S.A. Paschou, A.D. Dede, P. Anagnostis, A. Vryonidou, D. Morganstein, D.G. Goulis, Type 2 diabetes and osteoporosis: a guide to optimal management. J. Clin. Endocrinol. Metab. 102, 3621–3634 (2017).CrossRefPubMed S.A. Paschou, A.D. Dede, P. Anagnostis, A. Vryonidou, D. Morganstein, D.G. Goulis, Type 2 diabetes and osteoporosis: a guide to optimal management. J. Clin. Endocrinol. Metab. 102, 3621–3634 (2017).CrossRefPubMed
14.
Zurück zum Zitat A. Liberati, D.G. Altman, J. Tetzlaff et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339, 2700 (2009)CrossRef A. Liberati, D.G. Altman, J. Tetzlaff et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339, 2700 (2009)CrossRef
15.
Zurück zum Zitat A. Stang, Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25, 603–605 (2010).CrossRefPubMed A. Stang, Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25, 603–605 (2010).CrossRefPubMed
16.
Zurück zum Zitat P. Vestergaard, L. Rejnmark, L. Mosekilde, Are antiresorptive drugs effective against fractures in patients with diabetes? Calcif. Tissue Int. 88, 209–214 (2011)CrossRefPubMed P. Vestergaard, L. Rejnmark, L. Mosekilde, Are antiresorptive drugs effective against fractures in patients with diabetes? Calcif. Tissue Int. 88, 209–214 (2011)CrossRefPubMed
17.
Zurück zum Zitat R. Nan, D. Grigorie, A. Cursaru et al., Bisphosphonates-a good choice for women with type 2 diabetes and postmenopausal osteoporosis? Farmacia 64, 2 (2016) R. Nan, D. Grigorie, A. Cursaru et al., Bisphosphonates-a good choice for women with type 2 diabetes and postmenopausal osteoporosis? Farmacia 64, 2 (2016)
18.
Zurück zum Zitat T.H. Keegan, A.V. Schwartz, D.C. Bauer, D.E. Sellmeyer, J.L. Kelsey, Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care 27, 1547–1553 (2004)CrossRefPubMed T.H. Keegan, A.V. Schwartz, D.C. Bauer, D.E. Sellmeyer, J.L. Kelsey, Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care 27, 1547–1553 (2004)CrossRefPubMed
19.
Zurück zum Zitat J. Iwamoto, Y. Sato, M. Uzawa, T. Takeda, H. Matsumoto, Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. Diabetes Res. Clin. Pract. 93, 166–173 (2011)CrossRefPubMed J. Iwamoto, Y. Sato, M. Uzawa, T. Takeda, H. Matsumoto, Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. Diabetes Res. Clin. Pract. 93, 166–173 (2011)CrossRefPubMed
20.
Zurück zum Zitat S. Dagdelen, D. Sener, M. Bayraktar, Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. Adv. Ther. 24, 1314–1320 (2007)CrossRefPubMed S. Dagdelen, D. Sener, M. Bayraktar, Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. Adv. Ther. 24, 1314–1320 (2007)CrossRefPubMed
21.
Zurück zum Zitat D. Inoue, R. Muraoka, R. Okazaki, Y. Nishizawa, T. Sugimoto, Efficacy and safety of risedronate in osteoporosis subjectswith comorbid diabetes, hypertension, and/or dyslipidemia: a post hoc analysis of phase III trials conducted in Japan. Calcif. Tissue Int. 98, 114–122 (2016)CrossRefPubMed D. Inoue, R. Muraoka, R. Okazaki, Y. Nishizawa, T. Sugimoto, Efficacy and safety of risedronate in osteoporosis subjectswith comorbid diabetes, hypertension, and/or dyslipidemia: a post hoc analysis of phase III trials conducted in Japan. Calcif. Tissue Int. 98, 114–122 (2016)CrossRefPubMed
22.
Zurück zum Zitat O. Johnell, J.A. Kanis, D.M. Black et al., Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J. Bone Miner. Res. 19, 764–772 (2004)CrossRefPubMed O. Johnell, J.A. Kanis, D.M. Black et al., Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J. Bone Miner. Res. 19, 764–772 (2004)CrossRefPubMed
23.
Zurück zum Zitat K.E. Ensrud, J.L. Stock, E. Barrett-Connor et al., Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J. Bone Miner. Res. 23, 112–120 (2008)CrossRefPubMed K.E. Ensrud, J.L. Stock, E. Barrett-Connor et al., Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J. Bone Miner. Res. 23, 112–120 (2008)CrossRefPubMed
24.
Zurück zum Zitat A.V. Schwartz, I. Pavo, J. Alam et al., Teriparatide in patients with osteoporosis and type 2 diabetes. Bone 91, 152–158 (2016)CrossRefPubMed A.V. Schwartz, I. Pavo, J. Alam et al., Teriparatide in patients with osteoporosis and type 2 diabetes. Bone 91, 152–158 (2016)CrossRefPubMed
25.
Zurück zum Zitat A. Moayeri, M. Mohamadpour, S.F. Mousavi, E. Shirzadpour, S. Mohamadpour, M. Amraei, Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis. Ther. Clin. Risk. Manag. 13, 455–468 (2017)CrossRefPubMedPubMedCentral A. Moayeri, M. Mohamadpour, S.F. Mousavi, E. Shirzadpour, S. Mohamadpour, M. Amraei, Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis. Ther. Clin. Risk. Manag. 13, 455–468 (2017)CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat J. Dytfeld, M. Michalak, Type 2 diabetes and risk of low-energy fractures in postmenopausal women: meta-analysis of observational studies. Aging Clin. Exp. Res. 29, 301–309 (2017)CrossRefPubMed J. Dytfeld, M. Michalak, Type 2 diabetes and risk of low-energy fractures in postmenopausal women: meta-analysis of observational studies. Aging Clin. Exp. Res. 29, 301–309 (2017)CrossRefPubMed
27.
Zurück zum Zitat Y. Fan, F. Wei, Y. Lang, Y. Liu, Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos. Int. 27, 219–228 (2016)CrossRefPubMed Y. Fan, F. Wei, Y. Lang, Y. Liu, Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos. Int. 27, 219–228 (2016)CrossRefPubMed
28.
Zurück zum Zitat E.A. De Waard, T.A. Van Geel, H.H. Savelberg, A. Koster, P.P. Geusens, J.P. van den Bergh, Increased fracture risk in patients with type 2 diabetes mellitus: an overview of the underlying mechanisms and the usefulness of imaging modalities and fracture risk assessment tools. Maturitas 79, 265–274 (2014)CrossRefPubMed E.A. De Waard, T.A. Van Geel, H.H. Savelberg, A. Koster, P.P. Geusens, J.P. van den Bergh, Increased fracture risk in patients with type 2 diabetes mellitus: an overview of the underlying mechanisms and the usefulness of imaging modalities and fracture risk assessment tools. Maturitas 79, 265–274 (2014)CrossRefPubMed
29.
Zurück zum Zitat L. Ma, L. Oei, L. Jiang et al., Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur. J. Epidemiol. 27, 319–332 (2012)CrossRefPubMedPubMedCentral L. Ma, L. Oei, L. Jiang et al., Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur. J. Epidemiol. 27, 319–332 (2012)CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat G.I. Schacter, W.D. Leslie, DXA-based measurements in diabetes: can they predict fracture risk? Calcif. Tissue Int. 100, 150–164 (2017)CrossRefPubMed G.I. Schacter, W.D. Leslie, DXA-based measurements in diabetes: can they predict fracture risk? Calcif. Tissue Int. 100, 150–164 (2017)CrossRefPubMed
31.
Zurück zum Zitat L.M. Giangregorio, W.D. Leslie, L.M. Lix, H. Johansson, A. Oden, E. McCloskey, J.A. Kanis, FRAX underestimates fracture risk in patients with diabetes. J. Bone Miner. Res. 27, 301–8 (2012)CrossRefPubMed L.M. Giangregorio, W.D. Leslie, L.M. Lix, H. Johansson, A. Oden, E. McCloskey, J.A. Kanis, FRAX underestimates fracture risk in patients with diabetes. J. Bone Miner. Res. 27, 301–8 (2012)CrossRefPubMed
32.
Zurück zum Zitat A.V. Schwartz, E. Vittinghoff, D.C. Bauer, T.A. Hillier, E.S. Strotmeyer, K.E. Ensrud, M.G. Donaldson, J.A. Cauley, T.B. Harris, A. Koster, C.R. Womack, L. Palermo, D.M. Black, Study of Osteoporotic Fractures (SOF) Research Group; Osteoporotic Fractures in Men (MrOS) Research Group; Health, Aging, and Body Composition (Health ABC) Research Group. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 305(21), 2184–92 (2011)CrossRefPubMedPubMedCentral A.V. Schwartz, E. Vittinghoff, D.C. Bauer, T.A. Hillier, E.S. Strotmeyer, K.E. Ensrud, M.G. Donaldson, J.A. Cauley, T.B. Harris, A. Koster, C.R. Womack, L. Palermo, D.M. Black, Study of Osteoporotic Fractures (SOF) Research Group; Osteoporotic Fractures in Men (MrOS) Research Group; Health, Aging, and Body Composition (Health ABC) Research Group. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 305(21), 2184–92 (2011)CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat J.H. Kim, H.J. Choi, E.J. Ku et al., Trabecular bone score as an indicator for skeletal deterioration in diabetes. J. Clin. Endocrinol. Metab. 100, 475–482 (2015)CrossRefPubMed J.H. Kim, H.J. Choi, E.J. Ku et al., Trabecular bone score as an indicator for skeletal deterioration in diabetes. J. Clin. Endocrinol. Metab. 100, 475–482 (2015)CrossRefPubMed
34.
Zurück zum Zitat W.D. Leslie, B. Aubry-Rozier, O. Lamy, D. Hans, Manitoba bone density program. TBS (trabecular bone score) and diabetes-related fracture risk. J. Clin. Endocrinol. Metab. 98(2), 602–9 (2013)CrossRefPubMed W.D. Leslie, B. Aubry-Rozier, O. Lamy, D. Hans, Manitoba bone density program. TBS (trabecular bone score) and diabetes-related fracture risk. J. Clin. Endocrinol. Metab. 98(2), 602–9 (2013)CrossRefPubMed
35.
Zurück zum Zitat A.J. Burghardt, A.S. Issever, A.V. Schwartz et al., High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 95, 5045–5055 (2010)CrossRefPubMedPubMedCentral A.J. Burghardt, A.S. Issever, A.V. Schwartz et al., High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 95, 5045–5055 (2010)CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat A.G. Nilsson, D. Sundh, L. Johansson et al., Type 2 diabetes mellitus is associated with better bone microarchitecture but lower bone material Strength and poorer physical function in elderly women: a population-based Study. J. Bone Miner. Res. 32, 1062–1071 (2017)CrossRefPubMed A.G. Nilsson, D. Sundh, L. Johansson et al., Type 2 diabetes mellitus is associated with better bone microarchitecture but lower bone material Strength and poorer physical function in elderly women: a population-based Study. J. Bone Miner. Res. 32, 1062–1071 (2017)CrossRefPubMed
37.
Zurück zum Zitat J. Starup-Linde, S.A. Eriksen, S. Lykkeboe, A. Handberg, P. Vestergaard, Biochemical markers of bone turnover in diabetes patients-a meta-analysis, and a methodological study on the effects of glucose on bone markers. Osteoporos 25, 1697–1708 (2014)CrossRef J. Starup-Linde, S.A. Eriksen, S. Lykkeboe, A. Handberg, P. Vestergaard, Biochemical markers of bone turnover in diabetes patients-a meta-analysis, and a methodological study on the effects of glucose on bone markers. Osteoporos 25, 1697–1708 (2014)CrossRef
38.
Zurück zum Zitat J. Starup-Linde, Diabetes, biochemical markers of bone turnover, diabetes control, and bone. Front. Endocrinol. 4, 21 (2013)CrossRef J. Starup-Linde, Diabetes, biochemical markers of bone turnover, diabetes control, and bone. Front. Endocrinol. 4, 21 (2013)CrossRef
39.
Zurück zum Zitat V.N.Shah, K.K.Harrall, C.S.Shah, et al., Bone mineral density at femoral neck and lumbar spine in adults with type 1 diabetes: a meta-analysis and review of the literature. Osteoporos. Int 28, 2601–2610 (2017).CrossRefPubMed V.N.Shah, K.K.Harrall, C.S.Shah, et al., Bone mineral density at femoral neck and lumbar spine in adults with type 1 diabetes: a meta-analysis and review of the literature. Osteoporos. Int 28, 2601–2610 (2017).CrossRefPubMed
40.
Zurück zum Zitat J. Starup-Linde, S. Lykkeboe, S. Gregersen et al., Bone structure and predictors of fracture in type 1 and type 2 diabetes. J. Clin. Endocrinol. Metab. 101, 928–936 (2016)CrossRefPubMed J. Starup-Linde, S. Lykkeboe, S. Gregersen et al., Bone structure and predictors of fracture in type 1 and type 2 diabetes. J. Clin. Endocrinol. Metab. 101, 928–936 (2016)CrossRefPubMed
41.
Zurück zum Zitat C. Verroken, W. Pieters, L. Beddeleem et al., Cortical bone size deficit in adult patients with type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 102, 2887–2895 (2017)CrossRefPubMed C. Verroken, W. Pieters, L. Beddeleem et al., Cortical bone size deficit in adult patients with type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 102, 2887–2895 (2017)CrossRefPubMed
42.
Zurück zum Zitat M.M. Campos Pastor, J.D. Luna, F. Escobar-Jimenez, F.J. Gomez Jimenez, M.D. Serrano Pardo, P. Lopez-Ibarra, Effects of risedronate on metabolic bone disease in patients with type 1 diabetes and osteoporosis. Rev. Esp. Enferm. Metab. Oseas. 17, 66–70 (2008) M.M. Campos Pastor, J.D. Luna, F. Escobar-Jimenez, F.J. Gomez Jimenez, M.D. Serrano Pardo, P. Lopez-Ibarra, Effects of risedronate on metabolic bone disease in patients with type 1 diabetes and osteoporosis. Rev. Esp. Enferm. Metab. Oseas. 17, 66–70 (2008)
43.
Zurück zum Zitat R.E. Aubert, V. Herrera, W. Chen, S.M. Haffner, M. Pendergrass, Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes. Metab. 12, 716–721 (2010)CrossRefPubMed R.E. Aubert, V. Herrera, W. Chen, S.M. Haffner, M. Pendergrass, Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes. Metab. 12, 716–721 (2010)CrossRefPubMed
Metadaten
Titel
Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review
verfasst von
Panagiotis Anagnostis
Stavroula A. Paschou
Nifon N. Gkekas
Aikaterini-Maria Artzouchaltzi
Konstantinos Christou
Dimitrios Stogiannou
Andromachi Vryonidou
Michael Potoupnis
Dimitrios G. Goulis
Publikationsdatum
06.02.2018
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2018
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1548-x

Weitere Artikel der Ausgabe 3/2018

Endocrine 3/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.